P968: ADDITION OF IXAZOMIB TO POMALIDOMIDE AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL FOR MULTIPLE MYELOMA PATIENTS PROGRESSING ON LENALIDOMIDE AS PART OF 1ST LINE THERAPY: ALLIANCE A061202
P. Voorhees,
V. Suman,
Y. Efebera,
N. Raje,
S. Tuchman,
C. Rodriguez,
K. Santo,
M. Bova-Solem,
D. Carlisle,
U. Saad,
P. McCarthy,
P. Richardson
Affiliations
P. Voorhees
1 Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte
V. Suman
2 Alliance Statistics and Data Management Center, Mayo Clinic, Rochester
Y. Efebera
3 Department of Hematology and Oncology, Ohio Health, Columbus
N. Raje
4 Division of Hematology and Oncology, Massachusetts General Hospital, HArvard Medical School, Boston
S. Tuchman
5 Division of Hematology, Lineberger Comprehensive Cancer Center, the University of North Carolina, Chapel Hill
C. Rodriguez
6 Tisch Cancer Institute, Mount Sinai School of Medicine, New York City
K. Santo
2 Alliance Statistics and Data Management Center, Mayo Clinic, Rochester
M. Bova-Solem
7 Protocol Operations Program, Alliance for Clinical Trials in Oncology, Chicago
D. Carlisle
7 Protocol Operations Program, Alliance for Clinical Trials in Oncology, Chicago
U. Saad
8 Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York City
P. McCarthy
9 Transplant and Cellular Therapy Program, Roswell Park Comprehensive Cancer Center, Buffalo
P. Richardson
10 Department of Hematology and Oncology, Dana Farber Cancer Institute / Partners Cancer Care, Harvard Medical School, Boston, United States of America
